Evidence map›Paper›PMID 34897289›Full record

ArticleEuropean journal of human genetics : EJHG2022

Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study.

Claire Forde, Emma Burkitt-Wright, Peter D Turnpenny, Eric Haan, John Ealing, Sahar Mansour, Muriel Holder, Nayana Lahiri, Abhijit Dixit, Annie Procter and 19 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. 2022: the year that was in the European Journal of Human Genetics.European journal of human genetics : EJHG · 2023
    Article
  8. Article
  9. Good genotype-phenotype relationships in rare disease are hard to find.European journal of human genetics : EJHG · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 19 institutions in 4 countries.

Claire FordeManchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.ORCID 0000-0001-8035-4471
Emma Burkitt-WrightManchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Peter D TurnpennyClinical Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Eric HaanSouth Australia Clinical Genetics Services, North Adelaide, SA, Australia.
John EalingManchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Sahar MansourDepartment Of Clinical Genetics, St George's University NHS Foundation Trust, London, UK.ORCID 0000-0001-6629-4118
Muriel HolderGenetics Service, South East Thames Regional Genetics Service, London, UK.
Nayana LahiriDepartment Of Clinical Genetics, St George's University NHS Foundation Trust, London, UK.ORCID 0000-0002-6260-7700
Abhijit DixitClinical Genetics Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Annie ProcterAll Wales Medical Genetics Service, Cardiff, UK.
Laurence PacotService de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP.Centre-Université de Paris, Paris, France and Institut Cochin, Inserm U1016-CNRS UMR8104-Université de Paris, CARPEM, Paris, France.
Dominique VidaudService de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP.Centre-Université de Paris, Paris, France and Institut Cochin, Inserm U1016-CNRS UMR8104-Université de Paris, CARPEM, Paris, France.
Yline CapriDepartment of Clinical Genetics, Robert-Debré Hospital, AP-HP and University of Paris-Diderot, Paris, France.
Marion GerardService de Génétique Médicale, CHU Caen, Caen, France.
Hélène DollfusCentre de Référence Pour les Affections Rares en Génétique Ophtalmologique, CARGO, Filière SENSGENE, Hôpitaux Universitaires de Strasbourg; Medical Genetics Laboratory, INSERM U1112, Institute of Medical Genetics of Alsace, Strasbourg Medical School, University of Strasbourg, Strasbourg, France.
Elise SchaeferService de Génétique Médicale, Hôpitaux Universitaires de Strasbourg, Institut de Génétique Médicale d'Alsace, Strasbourg, France.
Chloé QuelinService de génétique clinique, CLAD Ouest, CHU Rennes, Hôpital Sud, Rennes, France.
Sabine SigaudyDepartment of Medical Genetics, Children's Hospital La Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Tiffany BusaDepartment of Medical Genetics, Children's Hospital La Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Gabriella VeraDepartment of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Rouen, France.ORCID 0000-0001-8352-5563
Lena DamajDepartment of Pediatrics, Competence Center of Inherited Metabolic Disorders, Rennes University Hospital, Rennes, France.
Ludwine MessiaenDepartment of Genetics, University of Alabama at Birmingham, Alabama, USA.
David A StevensonDivision of Medical Genetics, Department of Paediatrics, Stanford University, Stanford, USA.
Peter DaviesAll Wales Medical Genetics Service, Cardiff, UK.
Sheila Palmer-SmithAll Wales Medical Genetics Service, Cardiff, UK.
Alison CallawayMolecular Genetics, Salisbury NHS Foundation Trust, Salisbury, UK.
Pierre WolkensteinDépartement de Dermatologie, AP-HP and UPEC, Hôpital Henri-Mondor, Créteil, France.
Eric PasmantService de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP.Centre-Université de Paris, Paris, France and Institut Cochin, Inserm U1016-CNRS UMR8104-Université de Paris, CARPEM, Paris, France.
Meena UpadhyayaDivision of Cancer and Genetics, Cardiff University, Cardiff, UK. upadhyaya@cardiff.ac.uk.ORCID 0000-0002-4881-0235
Centre National de la Recherche Scientifique · FRUniversity of Manchester · GBAssistance Publique Hôpitaux de Marseille · FRSt George’s University Hospitals NHS Foundation Trust · GBCardiff University · GBCentre Hospitalier Universitaire de Caen Normandie · FRCentre Hospitalier Universitaire de Rennes · FRDélégation Paris 7 · FRHôpital Nord · FRHôpitaux Universitaires de Strasbourg · FRInserm · FRNottingham University Hospitals NHS Trust · GBRoyal Devon & Exeter NHS Foundation Trust · GBSalisbury NHS Foundation Trust · GBSouth Australia Pathology · AUStanford University · USUniversité Paris-Est Créteil · FRUniversity of Alabama at Birmingham · USWessex Regional Genetics Laboratory · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals with the three base pair deletion NM_000267.3(NF1):c.2970_2972del p.(Met992del) have been recognised to present with a milder neurofibromatosis type 1 (NF1) phenotype characterised by café-au-lait macules (CALs) and intertriginous freckling, as well as a lack of cutaneous, subcutaneous and plexiform neurofibromas and other NF1-associated complications. Examining large cohorts of patients over time with this specific genotype is important to confirm the presentation and associated risks of this variant across the lifespan. Forty-one individuals with the in-frame NF1 deletion p.Met992del were identified from 31 families. Clinicians completed a standardised clinical questionnaire for each patient and the resulting data were collated and compared to published cohorts. Thirteen patients have been previously reported, and updated clinical information has been obtained for these individuals. Both CALs and intertriginous freckling were present in the majority of individuals (26/41, 63%) and the only confirmed features in 11 (27%). 34/41 (83%) of the cohort met NIH diagnostic criteria. There was a notable absence of all NF1-associated tumour types (neurofibroma and glioma). Neurofibroma were observed in only one individual-a subcutaneous lesion (confirmed histologically). Nineteen individuals were described as having a learning disability (46%). This study confirms that individuals with p.Met992del display a mild tumoural phenotype compared to those with 'classical', clinically diagnosed NF1, and this appears to be the case longitudinally through time as well as at presentation. Learning difficulties, however, appear to affect a significant proportion of NF1 subjects with this phenotype. Knowledge of this genotype-phenotype association is fundamental to accurate prognostication for families and caregivers.

Indexed as

NeurofibromaNeurofibromatosis 1Cafe-au-Lait SpotsGenetic Association StudiesHumansLongitudinal Studies

Identifiers

PMID34897289
PMCPMC8904810
OpenAlexW4200549608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.